ES2320665T3 - Anticuerpos especificos del factor ixa que presentan una actividad analoga a la del factor viiia. - Google Patents

Anticuerpos especificos del factor ixa que presentan una actividad analoga a la del factor viiia. Download PDF

Info

Publication number
ES2320665T3
ES2320665T3 ES04764918T ES04764918T ES2320665T3 ES 2320665 T3 ES2320665 T3 ES 2320665T3 ES 04764918 T ES04764918 T ES 04764918T ES 04764918 T ES04764918 T ES 04764918T ES 2320665 T3 ES2320665 T3 ES 2320665T3
Authority
ES
Spain
Prior art keywords
antibody
factor
antibodies
seq
fixa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04764918T
Other languages
English (en)
Spanish (es)
Inventor
Friedrich Scheiflinger
Randolf Kerschbaumer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Healthcare SA
Baxter International Inc
Original Assignee
Baxter Healthcare SA
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34273861&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2320665(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Healthcare SA, Baxter International Inc filed Critical Baxter Healthcare SA
Application granted granted Critical
Publication of ES2320665T3 publication Critical patent/ES2320665T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES04764918T 2003-09-12 2004-09-07 Anticuerpos especificos del factor ixa que presentan una actividad analoga a la del factor viiia. Expired - Lifetime ES2320665T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US661366 2003-09-12
US10/661,366 US7297336B2 (en) 2003-09-12 2003-09-12 Factor IXa specific antibodies displaying factor VIIIa like activity

Publications (1)

Publication Number Publication Date
ES2320665T3 true ES2320665T3 (es) 2009-05-27

Family

ID=34273861

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04764918T Expired - Lifetime ES2320665T3 (es) 2003-09-12 2004-09-07 Anticuerpos especificos del factor ixa que presentan una actividad analoga a la del factor viiia.

Country Status (9)

Country Link
US (1) US7297336B2 (https=)
EP (1) EP1660536B1 (https=)
JP (1) JP4887148B2 (https=)
AT (1) ATE419277T1 (https=)
AU (1) AU2004271706B2 (https=)
CA (1) CA2538895A1 (https=)
DE (1) DE602004018788D1 (https=)
ES (1) ES2320665T3 (https=)
WO (1) WO2005025615A2 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT411997B (de) * 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
CA2603264C (en) * 2005-04-08 2017-03-21 Chugai Seiyaku Kabushiki Kaisha Antibody substituting for function of blood coagulation factor viii
EP1760092A1 (en) * 2005-08-26 2007-03-07 Applied Research Systems ARS Holding N.V. System for screening cells for high expression of a protein of interest
ES2892925T3 (es) 2006-03-31 2022-02-07 Chugai Pharmaceutical Co Ltd Métodos para controlar la farmacocinética en sangre de anticuerpos
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
PH12016502073B1 (en) 2010-11-17 2024-04-05 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
CN104937423B (zh) * 2012-09-28 2017-05-24 中外制药株式会社 凝血反应的评价方法
JP6534615B2 (ja) 2013-09-27 2019-06-26 中外製薬株式会社 ポリペプチド異種多量体の製造方法
AU2015229448B2 (en) 2014-03-11 2020-09-03 The Board Of Trustees Of The Leland Stanford Junior University Anti SIRP-alpha antibodies and Bi-specific Macrophage Enhancing antibodies
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
TWI701435B (zh) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
US20200270363A1 (en) 2015-12-25 2020-08-27 Chugai Seiyaku Kabushiki Kaisha Antibody having enhanced activity, and method for modifying same
CN108368166B (zh) 2015-12-28 2023-03-28 中外制药株式会社 提高含fc区多肽纯化效率的方法
MA44780A (fr) 2016-04-28 2019-03-06 Chugai Pharmaceutical Co Ltd Préparation contenant un anticorps
CN109563154B (zh) * 2016-05-16 2024-12-13 武田药品工业株式会社 抗帕多瓦因子ix抗体
KR102591955B1 (ko) 2016-07-29 2023-10-19 추가이 세이야쿠 가부시키가이샤 증강된 fviii 보인자 기능 대체 활성을 갖는 이중특이성 항체
RU2766233C2 (ru) 2016-09-06 2022-02-10 Чугаи Сейяку Кабусики Кайся Способы применения биспецифического антитела, которое распознает фактор свертывания ix и/или активированный фактор свертывания ix и фактор свертывания x и/или активированный фактор свертывания x
WO2018053597A1 (en) * 2016-09-23 2018-03-29 Csl Limited Coagulation factor binding proteins and uses thereof
US20230192896A1 (en) * 2016-11-23 2023-06-22 Bioverativ Therapeutics Inc. Bispecific antibodies binding to coagulation factor ix and coagulation factor x
EP3577140A1 (en) 2017-02-01 2019-12-11 Novo Nordisk A/S Procoagulant antibodies
CN110461358A (zh) 2017-03-31 2019-11-15 公立大学法人奈良县立医科大学 可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
AR113142A1 (es) 2017-09-29 2020-01-29 Chugai Pharmaceutical Co Ltd Moléculas de unión al antígeno multiespecíficas que tienen actividad de sustitución de la función de cofactor del factor viii de coagulación de sangre (fviii), y formulaciones farmacéuticas que contienen dicha molécula como ingrediente activo
AU2018361430B2 (en) 2017-11-01 2025-08-14 Chugai Seiyaku Kabushiki Kaisha Antibody variant and isoform with lowered biological activity
JP6761142B1 (ja) 2018-08-01 2020-09-23 ノヴォ ノルディスク アー／エス 改良された血液凝固促進抗体
US11220554B2 (en) 2018-09-07 2022-01-11 Novo Nordisk A/S Procoagulant antibodies
PL3723858T3 (pl) 2018-12-21 2022-03-07 Kymab Limited Przeciwciało dwuswoiste fixaxfx o wspólnym łańcuchu lekkim
CN115052898B (zh) 2020-01-30 2025-09-16 诺和诺德股份有限公司 双特异性因子viii模拟抗体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT368883B (de) 1980-07-22 1982-11-25 Immuno Ag Verfahren zur herstellung einer neuen blutgerinnungsfoerdernden praeparation auf basis von humanproteinen
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
CA2143125C (en) 1992-08-27 2008-09-23 Koenraad Mertens Antibodies specific for a haemostatic protein, their use for isolating intact protein, haemostatic compositions devoid of proteolytic cleavage products of the protein
DK128093D0 (da) 1993-11-12 1993-11-12 Novo Nordisk As Hidtil ukendte forbindelser
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
WO1999001476A1 (en) 1997-07-03 1999-01-14 Smithkline Beecham Corporation CRYSTAL STRUCTURES OF ANTI-FACTOR IX Fab FRAGMENTS AND METHODS OF USE FOR PEPTIDOMIMETIC DESIGN
AT411997B (de) * 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
CU23007A1 (es) * 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
PT1383785E (pt) * 2001-05-03 2011-06-28 Merck Patent Gmbh Anticorpo recombinante específico de tumores e utilização deste

Also Published As

Publication number Publication date
AU2004271706A1 (en) 2005-03-24
JP4887148B2 (ja) 2012-02-29
EP1660536A2 (en) 2006-05-31
US20050058640A1 (en) 2005-03-17
AU2004271706B2 (en) 2010-09-02
DE602004018788D1 (de) 2009-02-12
WO2005025615A2 (en) 2005-03-24
EP1660536B1 (en) 2008-12-31
JP2007504812A (ja) 2007-03-08
CA2538895A1 (en) 2005-03-24
WO2005025615A3 (en) 2005-06-02
ATE419277T1 (de) 2009-01-15
US7297336B2 (en) 2007-11-20

Similar Documents

Publication Publication Date Title
ES2320665T3 (es) Anticuerpos especificos del factor ixa que presentan una actividad analoga a la del factor viiia.
US12384854B2 (en) Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
ES2765418T3 (es) Anticuerpos monoclonales optimizados contra el inhibidor de la ruta del factor tisular (TFPI)
ES2288873T3 (es) Anticuerpos de activacion del factor ix/factor ixa.
ES2677329T3 (es) Anticuerpos monoclonales contra el inhibidor de la ruta del factor tisular (TFPI)
ES2726040T3 (es) Antagonistas de PCSK9
ES2494191T3 (es) Anticuerpo anti-adrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o andamiaje proteico sin Ig anti-ADM para su utilización en tratamientos
ES2494190T3 (es) Anticuerpo anti-adrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o andamiaje proteico sin Ig anti-ADM para reducir el riesgo de mortalidad en un paciente que padece una enfermedad crónica o aguda o un estado agudo
ES2642718T3 (es) Moléculas de anticuerpos que se unen a la trombina y usos de las mismas
JP2014506257A (ja) 血漿カリクレイン結合タンパク質
JP2020007354A (ja) 抗血漿カリクレイン抗体
ES2743423T3 (es) Conjugado de anticuerpos para su uso en el tratamiento de una enfermedad inflamatoria intestinal
US10144784B2 (en) Monoclonal antibodies against antithrombin beta
ES2277597T3 (es) Agentes antitromboticos.
TW202216210A (zh) 抗組織因子抗體－藥物共軛體類和彼等於治療癌症之用途
ES2119165T5 (es) Nueva actividad de cofactor anticoagulante.
ES2279598T3 (es) Polipeptidos de proteinas y sus usos.
ES2366280T3 (es) Anticuerpos antiidiotípicos contra un inhibidor del factor viii y usos de los mismos.
Gish Structural Studies of Complexes of Blood Coagulation Factor VIII
ES2727706T3 (es) Anticuerpos que reconocen la parte n-terminal del inhibidor de la vía del factor tisular capaz de provocar la actividad procoagulante
BR112018069283B1 (pt) Anticorpos monoclonais contra o sítio ativo de fator xi e usos dos mesmos